Ashish Life Science, a Mumbai, India-based generic veterinary pharmaceuticals company, raised INR 45 crores (approx. $6.3m) in Series A funding.
The round was led by Eight Roads Ventures India with participation from Anterra Capital.
The company intends to use the funds to scale the business in its current geographies and expand into regulated markets, such as Europe, Australia and South Africa.
Established by Raujesh Agarrwal in 2002, Ashish Life Science is an export focused, veterinary pharmaceuticals company, which has expanded operations to build out a 100+ product portfolio catering to several animal types, established a presence in over 50 countries and has grown its manufacturing infrastructure to produce injectable drugs as well.
The company has a manufacturing facility which is accredited with EU GMP, APVMA (Australian) GMP and other certifications from various health authorities.